The most striking findings appeared among men. Compared with men classified as normal weight, those in the overweight category had a 46% lower risk of mortality. Men with class I or class II obesity, corresponding to a BMI of 30 to less than 40 kilograms per square meter, had a 51% lower risk. These figures do not mean that gaining weight protects health, nor do they establish that obesity directly reduces mortality. They describe statistical associations observed in an older population, where body composition, pre-existing illness, muscle loss, smoking, functional decline and other factors can influence both BMI and survival. Nevertheless, the strength and direction of the association highlight why BMI can be difficult to interpret in older adults.

Waist circumference produced a very different signal. Among men, a high waist circumference was associated with a 24% higher mortality risk, even after BMI was taken into account. Similar patterns were observed in women, with higher BMI generally linked to lower mortality and greater waist circumference associated with higher risk. This distinction matters because BMI is calculated from weight and height but cannot determine how much of that weight comes from fat, muscle, bone or fluid. Two people with the same BMI can have very different body compositions and metabolic profiles. Waist circumference provides additional information about fat stored around the abdomen, although it is also an imperfect measure and can be influenced by body shape, age and measurement technique.

Abdominal fat is biologically important because fat deposited around internal organs, often called visceral adipose tissue, is metabolically active. Unlike much of the fat stored beneath the skin, visceral fat can contribute to chronic inflammation, insulin resistance, abnormal lipid levels and changes in blood pressure regulation. These processes are associated with cardiovascular disease, diabetes and other conditions that can increase mortality risk. A larger waist does not prove that an individual has harmful levels of visceral fat, but it can act as a practical clinical marker of increased cardiometabolic risk. The study’s findings therefore support the idea that waist circumference may reveal risk that is obscured when BMI is considered alone.

The researchers also examined BMI and waist circumference together rather than treating them as separate measurements. Among men, being overweight was associated with a lower mortality risk regardless of whether waist circumference was elevated. Class I and class II obesity were also associated with lower mortality, but this relationship was observed exclusively among men who had an elevated waist circumference. That counterintuitive result reinforces the complexity of interpreting weight in older age. It may reflect differences in muscle mass, patterns of weight loss before death, the presence of chronic disease or other characteristics that cannot be fully captured by BMI categories. It also demonstrates that the relationship between body measurements and mortality is not necessarily linear or uniform across groups.

The clearest adverse patterns involved low weight and the combination of a normal BMI with an enlarged waist. Being underweight, regardless of waist circumference, was associated with a higher mortality risk in both men and women. Normal-weight adults with elevated waist circumference also faced higher risk in both sexes. In older adults, low body weight can sometimes accompany frailty, loss of muscle tissue, poor appetite, chronic disease or unintentional weight loss. A normal BMI may similarly conceal a condition sometimes described as sarcopenic obesity, in which a person has relatively low muscle mass alongside excess fat. These possibilities help explain why a seemingly reassuring BMI may not always indicate low risk.

The results fit into a long-running debate over the so-called obesity paradox in aging research. In some studies of older adults, overweight or modest obesity has been associated with better survival than normal weight, a pattern that appears to contradict conventional expectations. Several explanations have been proposed. Extra energy reserves may be useful during serious illness, and people with higher body weight may receive medical attention earlier or differ in ways that are not fully measured. Conversely, normal-weight groups can include former smokers or people who have lost weight because of illness, while BMI does not distinguish muscle from fat. Statistical adjustment can reduce some of these effects, but observational studies cannot eliminate every source of confounding.

The study used time-varying measurements of BMI and waist circumference, an approach designed to account for changes in body size over the follow-up period rather than relying on a single measurement taken at the beginning. This is important because weight and waist size can change substantially in later life. A stable body weight, gradual weight gain, rapid weight loss and loss of muscle can have very different clinical meanings, even when the final BMI category is identical. By evaluating measurements over time, the analysis sought to provide a more realistic picture of how changing body size relates to mortality. However, the findings remain observational: they show how variables move together in a population and do not demonstrate that changing BMI or waist circumference would directly change an individual’s chance of survival.

Bryan Blissmer, PhD, of the University of Rhode Island and a co-author of the study, said BMI and waist circumference provide complementary information about health in older adults. The findings suggest that clinicians may obtain a more informative assessment by considering both measurements, alongside age, sex, muscle strength, physical function, medical history, nutrition and patterns of weight change. The message is not that BMI should be abandoned or that obesity is harmless. Rather, the analysis indicates that BMI alone can miss important differences in abdominal fat and frailty risk. For an aging population, a broader assessment of body composition and health status may help clinicians identify vulnerable patients more accurately and make better-informed decisions about prevention and care.

Subject of Research: The relationship between time-varying body mass index, waist circumference and all-cause mortality in US adults aged 65 and older.

Article Title: Time-varying body mass index, waist circumference and all-cause mortality in US adults aged 65 or older

News Publication Date: 19-Aug-2026

Web References: https://doi.org/10.1111/jgs.70600

References: Journal of the American Geriatrics Society, DOI: 10.1111/jgs.70600

Keywords: body mass index, BMI, waist circumference, abdominal obesity, older adults, geriatrics, mortality risk, all-cause mortality, aging, public health, body composition, obesity paradox

The concept of “clinical obesity,” introduced by the Lancet Diabetes & Endocrinology Commission, aims to transcend the limitations of BMI alone by including assessments of body fat distribution and evidence of compromised organ or physical function. This approach attempts to address the disconnect between a normal or overweight BMI and the presence of metabolic and functional impairments caused by excess adiposity that BMI cannot detect. Anthropometric tools such as waist circumference, waist-to-hip ratio, and waist-to-height ratio provide critical insight into central adiposity—the fat deposited around vital organs—that BMI fails to quantify effectively.

Researchers at the University of Southern California led an analysis utilizing data from the 2021–2023 National Health and Nutrition Examination Survey (NHANES), a comprehensive and representative survey of the U.S. population. They examined over five thousand adults, evaluating their BMI, various anthropometric measures, and physiological indicators suggestive of reduced organ or physical function. The study’s cross-sectional design enabled the researchers to estimate how clinical obesity prevalence differs when relying on multifaceted criteria rather than isolated BMI cutoffs.

Remarkably, the data revealed that approximately one-quarter of adults classified within the normal BMI range exhibit clinical obesity—a condition characterized by excess adiposity coupled with early signs of organ or physical dysfunction. Furthermore, more than half of those categorized as overweight based solely on BMI met the clinical obesity criteria. These findings imply that a substantial subset of individuals presumed to be at lower risk according to BMI might actually bear significant health vulnerabilities associated with excess fat accumulation and its metabolic consequences.

When the threshold for defining excess adiposity included multiple abnormal anthropometric indicators rather than BMI alone, the prevalence of fat-related health risks soared dramatically. Nearly 78% of participants showed signs of excess adiposity when considering two or three abnormal anthropometric measures. This contrasts starkly with the roughly 41% prevalence when relying on an abnormal BMI combined with one anthropometric abnormality. The discrepancy underscores the utility of multi-parameter assessments in uncovering hidden health detriments not detected by BMI-focused screening.

These insights have profound implications for clinical practice. Physicians and health systems traditionally depend on BMI as a quick screening tool due to its simplicity and ease of use, but this research suggests that relying on BMI alone may overlook many patients at risk for obesity-related diseases. Introducing comprehensive assessments, including waist circumference and other anthropometric evaluations, paired with functional and organ health indicators, may improve diagnostic accuracy, enabling earlier intervention and more personalized care strategies.

From a pathophysiological perspective, the accumulation of visceral fat—fat stored in the abdominal cavity—plays a central role in driving metabolic syndrome, insulin resistance, type 2 diabetes, cardiovascular disease, and other complications frequently attributed to obesity. BMI lacks sensitivity to distinguish between subcutaneous fat, which lies beneath the skin, and the more dangerous visceral fat enveloping internal organs. This distinction is crucial, as excess visceral fat triggers inflammation, hormonal disruptions, and organ damage long before weight gain becomes apparent on conventional BMI scales.

Incorporating clinical obesity criteria can also better align treatment decisions with patients’ actual health status rather than simply their weight. It may steer healthcare providers towards recommending more intensive lifestyle interventions, pharmacotherapy, or monitoring in individuals who appear “normal weight” but harbor underlying fat-associated impairments. Conversely, it can prevent unnecessary alarm or overtreatment in those who have a high BMI by muscle mass or other benign factors, thus promoting more equitable and effective patient care.

The study’s findings support a growing consensus in the medical community that a paradigm shift is needed to improve obesity diagnosis and management. Public health initiatives and clinical guidelines must adapt to encompass multifactorial evaluations of adiposity and its systemic effects. Such evolution is vital not only to enhance patient outcomes but to curb the escalating economic and societal burdens imposed by obesity-related chronic diseases.

While BMI’s convenience and historical precedent have made it an entrenched tool in both research and clinical settings, this evidence calls for integrating additional anthropometric and functional parameters. The cost-effectiveness and feasibility of these measures in routine practice will need further evaluation but offer a promising avenue to identify hidden risk and tailor interventions more precisely.

This research thus adds a critical layer of understanding to the complex phenotype of obesity, highlighting how a seemingly normal weight individual might be clinically obese. Recognizing and validating clinical obesity as a diagnostic entity may revolutionize how medical professionals perceive, diagnose, and treat excess adiposity and its pervasive impact on human health.

As the obesity epidemic continues unabated worldwide, these findings emphasize the urgency of refining diagnostic tools beyond BMI. Embracing a more nuanced and comprehensive evaluation framework could empower clinicians to detect early declines in organ and physical function linked to excess fat, ultimately improving prevention strategies and reducing morbidity and mortality associated with obesity’s silent progression.

Together with the evolving insights into adiposity’s role in metabolic and cardiovascular diseases, adopting clinical obesity criteria marks a forward step in personalized medicine—one that respects the intricate interplay between body composition, function, and long-term health risks. Future research should expand upon these initial findings to develop standardized and accessible protocols that can be seamlessly integrated into diverse healthcare settings globally.

Subject of Research: People
Article Title: National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study
News Publication Date: 2-Jun-2026
Web References: http://dx.doi.org/10.7326/ANNALS-25-05287
Keywords: Obesity, Clinical medicine, Body mass index

Metabolic syndrome—a constellation of interrelated metabolic disturbances—has long been implicated in cardiovascular diseases, but its association with cancer progression and survivorship is now emerging as equally consequential. Defined by the American Heart Association as the presence of at least three out of five risk factors, metabolic syndrome includes elevated blood pressure, increased triglycerides, reduced high-density lipoprotein (HDL) cholesterol, high fasting glucose levels, and central obesity measured by waist circumference. In women, a waist measurement exceeding 35 inches signals increased risk. These metabolic irregularities create a chronic pathological environment that may accelerate cancer progression and impair recovery.

The comprehensive study, which pooled data from over 42,000 breast cancer survivors, combined survival statistics from observational cohorts and randomized controlled trials to construct robust survival ratio models. This synthesis revealed that those diagnosed with metabolic syndrome had a staggering 69% increased risk of breast cancer recurrence and an 83% increased likelihood of succumbing to the disease compared to those without metabolic abnormalities. Notably, survivors with metabolic syndrome were also 57% more prone to breast cancer-related adverse events, including recurrence, new cancer formation, or death, highlighting a broadly detrimental impact on survivorship.

One of the remarkable aspects of this research lies in its extensive geographic scope. By including studies from Europe, North America, and Asia, the authors confirm that the association between metabolic syndrome and worsened breast cancer outcomes holds true across diverse ethnic and healthcare settings. This universality suggests that metabolic health is a fundamental determinant of cancer prognosis rather than a confounding regional or genetic factor. Thus, addressing metabolic dysfunction could become a pivotal component of global breast cancer survivorship strategies.

The biological mechanisms underpinning these associations, while not fully elucidated in the present study, are hypothesized to involve complex interactions between adiposity-related hormonal imbalances and chronic systemic inflammation. Excess body fat, particularly abdominal obesity, is known to elevate circulating estrogen levels, which can stimulate estrogen receptor-positive breast cancer cell proliferation. Moreover, adipose tissue secretes a variety of bioactive molecules that may modify the tumor microenvironment, promoting metastatic potential by enhancing cancer cell motility and invasion.

Chronic inflammation, a hallmark of metabolic syndrome, further exacerbates cancer progression by fostering an immunosuppressive milieu that hinders effective immune surveillance and supports malignant cell survival. Inflammatory cytokines and adipokines released from dysfunctional adipose tissue create a persistent state of low-grade systemic inflammation, which is increasingly recognized as a driver of tumor growth and metastatic dissemination. These overlapping pathophysiological pathways suggest that metabolic syndrome acts synergistically to impair cancer prognosis through multiple molecular avenues.

From a clinical perspective, these findings advocate for routine metabolic screening in breast cancer survivors to enable timely identification and management of metabolic syndrome. Interventions aimed at controlling hyperlipidemia, normalizing blood glucose, managing hypertension, and reducing central adiposity could not only mitigate cardiovascular risks but also directly improve cancer outcomes. Lifestyle modifications, including dietary changes, physical activity, and weight management, alongside pharmacologic therapies targeting metabolic disturbances, hold promise for enhancing survival rates in this vulnerable population.

This study also raises important considerations for future research aimed at disentangling the mechanistic links between metabolic health and breast cancer biology. Prospective trials investigating the effects of metabolic syndrome reversal on breast cancer recurrence and mortality are warranted to establish causality and inform evidence-based therapeutic guidelines. Moreover, exploring the molecular crosstalk between metabolic dysfunction and tumor microenvironment dynamics could reveal novel therapeutic targets for integrated cancer and metabolic disease management.

Public health implications of this research resonate strongly amid the global obesity epidemic, which increasingly overlaps with the rising burden of breast cancer. Breast cancer survivors represent a subgroup at heightened risk due to metabolic syndrome, necessitating tailored strategies that bridge oncology and metabolic health disciplines. Integrating metabolic health assessments into standard oncologic follow-up protocols may offer an invaluable opportunity to improve long-term survival outcomes and quality of life for millions of women worldwide.

Ultimately, this emerging paradigm calls for a multidisciplinary approach combining oncologists, endocrinologists, nutritionists, and exercise physiologists to holistically address metabolic syndrome in breast cancer survivorship care plans. Such collaboration will be crucial for translating these research insights into effective clinical interventions that curb cancer recurrence and reduce mortality. Empowering survivors with knowledge and resources to manage their metabolic health may prove transformative in the journey beyond cancer.

In conclusion, Dr. Harborg and colleagues’ meta-analytic research presents compelling evidence that metabolic syndrome is a potent adverse prognostic factor for breast cancer survivors. Their findings underscore the imperative to incorporate metabolic screening and management into survivorship care, with the potential to substantially mitigate recurrence risk and improve survival outcomes. As scientific inquiry advances, unraveling the molecular underpinnings of this association will be vital for developing innovative therapeutic entanglements that simultaneously target cancer and metabolic disease pathways.

This paradigm-shifting research published in The Journal of Internal Medicine illuminates how disturbances in metabolic homeostasis—manifesting as elevated blood pressure, dyslipidemia, hyperglycemia, and abdominal obesity—intersect with cancer biology to negatively influence breast cancer survivorship. By spotlighting metabolic syndrome as a key determinant of prognosis, this work opens new avenues for intervention and highlights the critical importance of metabolic health optimization in the holistic care of breast cancer survivors globally.

Subject of Research: Impact of metabolic syndrome on breast cancer recurrence and mortality in survivors

Article Title: [Not provided in source]

News Publication Date: [Not provided in source]

Web References: [Not provided in source]

References: Study to be published in The Journal of Internal Medicine, presented at ECO 2025, Malaga, Spain

Image Credits: [Not provided in source]

Keywords: Breast cancer survival, metabolic syndrome, obesity, chronic inflammation, cancer recurrence, estrogen, adiposity, tumor microenvironment, metabolic health, cancer mortality, survivorship care, epidemiology